0001472375-22-000012.txt : 20220202 0001472375-22-000012.hdr.sgml : 20220202 20220202141827 ACCESSION NUMBER: 0001472375-22-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220202 DATE AS OF CHANGE: 20220202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENEREX PHARMA, INC. CENTRAL INDEX KEY: 0001357878 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 980479983 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53230 FILM NUMBER: 22582861 BUSINESS ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: (702) 805-7525 MAIL ADDRESS: STREET 1: 5348 VEGAS DRIVE #177 CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20180309 FORMER COMPANY: FORMER CONFORMED NAME: Eternelle Skincare Products Inc. DATE OF NAME CHANGE: 20170621 FORMER COMPANY: FORMER CONFORMED NAME: PEPTIDE TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20111007 10-Q 1 ixform10q.htm QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2021
0001357878 false 2021 Q3 --03-31 0001357878 2021-04-01 2021-12-31 0001357878 2022-02-02 0001357878 2021-12-31 0001357878 2021-03-31 0001357878 2021-10-01 2021-12-31 0001357878 2020-10-01 2020-12-31 0001357878 2020-04-01 2020-12-31 0001357878 2020-03-31 0001357878 2020-12-31 0001357878 us-gaap:CommonStockMember 2020-03-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001357878 us-gaap:RetainedEarningsMember 2020-03-31 0001357878 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-09-30 0001357878 us-gaap:RetainedEarningsMember 2020-04-01 2020-09-30 0001357878 2020-04-01 2020-09-30 0001357878 us-gaap:CommonStockMember 2020-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001357878 us-gaap:RetainedEarningsMember 2020-09-30 0001357878 2020-09-30 0001357878 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001357878 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001357878 us-gaap:CommonStockMember 2020-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001357878 us-gaap:RetainedEarningsMember 2020-12-31 0001357878 us-gaap:CommonStockMember 2021-03-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001357878 us-gaap:RetainedEarningsMember 2021-03-31 0001357878 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-09-30 0001357878 us-gaap:RetainedEarningsMember 2021-04-01 2021-09-30 0001357878 2021-04-01 2021-09-30 0001357878 us-gaap:CommonStockMember 2021-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001357878 us-gaap:RetainedEarningsMember 2021-09-30 0001357878 2021-09-30 0001357878 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001357878 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001357878 us-gaap:CommonStockMember 2021-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001357878 us-gaap:RetainedEarningsMember 2021-12-31 0001357878 rep1357878:PurchaseIntellectualPropertyMember 2021-11-15 0001357878 2021-11-15 0001357878 2021-11-01 2021-11-15 0001357878 2021-01-01 2021-12-31 0001357878 2020-01-01 2020-12-31 0001357878 srt:ChiefExecutiveOfficerMember 2021-12-31 0001357878 srt:ChiefExecutiveOfficerMember 2020-12-31 0001357878 rep1357878:NotePayableToShareholderMember 2021-12-31 0001357878 rep1357878:NotePayableToShareholderMember 2021-03-31 0001357878 rep1357878:April15Note2021Member 2021-12-31 0001357878 rep1357878:April15Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October11Note2021Member 2021-12-31 0001357878 rep1357878:October11Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October21Note2021Member 2021-12-31 0001357878 rep1357878:October21Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October25Note2021Member 2021-12-31 0001357878 rep1357878:October25Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:December9Note2021Member 2021-12-31 0001357878 rep1357878:December9Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:PromissoryNote1Member 2022-01-01 2022-01-20 0001357878 rep1357878:PromissoryNote1Member 2022-01-20 0001357878 rep1357878:PromissoryNote2Member 2022-01-01 2022-01-31 0001357878 rep1357878:PromissoryNote2Member 2022-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2021

 

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

 

Commission File No. 000-53230



 

REGENEREX PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada

 

98-0479983

(State or other jurisdiction of

 

(IRS Employer

incorporation or organization)

 

Identification No.)

 

5348 Vegas Drive #177

Las Vegas, NV 89108

(Address of principal executive offices)

 

(702) 273-3772

Registrant’s telephone number, including area code

 

Peptide Technologies, Inc.

 (Former name or former address, if changed since last report.) 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X ] No [   ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

[  ]

Accelerated filer

[   ]

Non-Accelerated filer

[  ]

Smaller reporting company

[X]

 

 

Emerging growth company

[X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

  

Class

 

Outstanding at February 2, 2022

Common stock, $0.001 par value

 

277,112,660

“Explanatory Note Regarding Forward-Looking Statements:”

 

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

●     our ability to add new customers;

●     the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows;

●     the potential benefits of and our ability to maintain our relationships, and establish or maintain future collaborations or strategic relationships or obtain additional funding;

●     our marketing capabilities and strategy;

●     our ability to maintain a cost-effective program;

●     our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

●     our competitive position, and developments and projections relating to our competitors and our industry;

●     our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and

●     the impact of laws and regulations.

 

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.) 

INDEX TO FORM 10-Q FILING

FOR THE NINE MONTHS ENDED DECEMBER 31, 2021 AND 2020

TABLE OF CONTENTS

 

 

PAGE

PART I - FINANCIAL INFORMATION

 

 

 

Item 1.

Financial Statements (Unaudited)

1

 

Balance Sheets

1

 

Statements of Operations

2

 

Statements of Cash Flows

3

 

Statements of Stockholders’ Deficit

4

 

Notes to Financial Statements

5

Item 2.

Management Discussion & Analysis of Financial Condition and Results of Operations

10

Item 3

Quantitative and Qualitative Disclosures About Market Risk

14

Item 4.

Controls and Procedures

14

 

 

 

PART II - OTHER INFORMATION

 

 

 

Item 1.

Legal Proceedings

16

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

16

Item 3.

Defaults Upon Senior Securities

16

Item 4.

Mining Safety Disclosures

16

Item 5

Other Information

16

Item 6.

Exhibits

16

 

 

 

CERTIFICATIONS

 

 

 

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

 

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

 

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

 

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS



REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.)

BALANCE SHEETS

(UNAUDITED)

 

    December 31, 2021     March 31, 2021  
ASSETS            
             
Current Assets            
Cash and equivalents $ 2,789   $ 6,902  
Prepaid expenses   —     1,213  
Total Current Assets   2,789     8,115  
             
Website, net of accumulated amortization of $21,974 and $19,645, respectively   8,626     2,355  
Total Assets $ 11,415   $ 10,470  
             
LIABILITIES AND STOCKHOLDERS’ DEFICIT            
             
Current Liabilities            
Accounts payable $ 47,813   $ 48,038  
Related party advances   131,447     130,992  
Accrued compensation   221,192     221,192  
Other accrued liabilities   79,524     71,003  
Current portion of notes payable to shareholder   118,853     150,094  
Total Current Liabilities   598,829     621,319  
             
Notes payable to shareholder, net of current portion   349,754     224,177  
             
Total Liabilities   948,583     845,496  
             
Commitments and Contingencies (Note 7)            
             
Stockholders’ Deficit            
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively    277,113     127,113  
Additional paid-in capital   671,963     776,963  
Accumulated deficit   (1,886,244 )   (1,739,102)  
Total Stockholders’ Deficit   (937,168 )   (835,026)  
Total Liabilities and Stockholders’ Deficit $ 11,415   $ 10,470  

 

 The accompanying notes are an integral part of these unaudited financial statements.

1

 REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.)

STATEMENTS OF OPERATIONS

(UNAUDITED)

 

                         
    Three Months Ended     Nine months Ended  
    December 31,     December 31,  
    2021     2020     2021     2020  
                         
Sales $ —   $ 181   $ —   $ 378  
                         
Cost of Sales   —     364     —     406  
                         
Gross Loss   —     (183 )   —     (28 )
                         
Operating Expenses                        
General and administrative   62,385     12,103     100,192     33,229  
Sales and marketing   612     1,966     3,303     3,056  
Total Operating Expenses   62,997     14,069     103,495     36,285  
                         
Operating Loss   (62,997 )   (14,252 )   (103,495 )   (36,313 )
                         
Other Income (Expense)                        
Interest expense   (14,548 )   (11,203 )   (44,130 )   (31,335 )
Foreign currency gain (loss)   (1,889 )   (8,228 )   483     (1,624 )
Total Other Income (Expense)   (16,437 )   (19,431 )   (43,647 )   (32,959 )
                         
Net Loss $ (79,434 ) $ (33,683 ) $ (147,142 ) $ (69,272 )
                         
Basic and Diluted Loss per Common Share $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 )
Weighted Average Number of Common Shares Outstanding   203,743,095     127,112,660     152,749,024     127,112,660  

  

The accompanying notes are an integral part of these unaudited financial statements.

2

 REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.)

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

               
  For the Nine months Ended  
  December 31,  
  2021     2020  
Cash Flows from Operating Activities:              
Net loss $ (147,142 )   $ (69,272 )
Adjustments to reconcile net loss to cash flows used in operating activities:              
Depreciation   2,329       4,167  
Foreign currency adjustments   (483 )     1,624  
Stock-based compensation   45,000       —  
Changes in operating assets and liabilities:              
Inventories   —       406  
Prepaid expenses   1,213       (1,645 )
Accounts payable and accrued liabilities   36,033       27,168  
Net cash used in operating activities   (63,050 )     (37,552 )
               
Cash Flows from Investing Activities:              
Website   (8,600 )     —  
Net cash used in investing activities   (8,600 )     —  
               
Cash Flows from Financing Activities:              
Related party advances   455       —  
Proceeds from notes payable to shareholder   67,082       33,813  
Net cash provided by financing activities   67,537       33,813  
               
Decrease in cash and equivalents   (4,113 )     (3,739 )
Cash and cash equivalents, beginning of period   6,902       5,460  
Cash and cash equivalents, end of period $ 2,789     $ 1,721  
               
Supplemental Cash Flow Information – Cash Paid For:              
Income Taxes $ —     $ —  
Interest $ —     $ —  
Non-Cash Investing and Financing Activities:              
Accrued interest converted into note payable to shareholder $ 27,254     $ —  
Shares issued for the acquisition of intellectual property $ 150,000     $ —  

 

 The accompanying notes are an integral part of these unaudited financial statements.

3

 REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.) 

STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED) 

 

                                 
      Common Stock                    
      Shares     Amount     Additional Paid-in Capital     Accumulated Deficit     Stockholders’ Deficit  
Balance at March 31, 2020     127,112,660   $ 127,113   $ 776,963   $ (1,385,350 ) $ (481,274 )
Net loss     —     —     —     (35,589 )   (35,589 )
Balance at September 30, 2020     127,112,660   $ 127,113   $ 776,963   $ (1,420,939 ) $ (516,863 )
Balance at September 30, 2020     127,112,660   $ 127,113   $ 776,963   $ (1,420,939 ) $ (516,863 )
Net loss     —     —     —     (33,683 )   (33,683 )
Balance at December 31, 2020     127,112,660   $ 127,113   $ 776,963   $ (1,454,622 ) $ (550,546 )
                                 
Balance at March 31, 2021     127,112,660   $ 127,113   $ 776,963   $ (1,739,102 ) $ (835,026 )
Net loss     —     —     —     (67,708 )   (67,708 )
Balance at September 30, 2021     127,112,660   $ 127,113   $ 776,963   $ (1,806,810 ) $ (902,734 )
Balance at September 30, 2021     127,112,660   $ 127,113   $ 776,963   $ (1,806,810 ) $ (902,734 )
Common stock issued for purchase of intellectual property     150,000,000     150,000     (150,000 )   —     —  
Stock-based compensation     —     —     45,000     —     45,000  
Net loss     —     —     —     (79,434 )   (79,434 )
Balance at December 31, 2021     277,112,660   $ 277,113   $ 671,963   $ (1,886,244 ) $ (937,168 )

The accompanying notes are an integral part of these unaudited financial statements.

4

REGENEREX PHARMA, INC.

(FORMERLY PEPTIDE TECHNOLOGIES, INC.) 

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 – NATURE OF OPERATIONS

 

Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.  The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced.  The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.


On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.


Management has decided to focus on this new business development.

 

Risks and Uncertainties 


Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.


The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.

 

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2021 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2021 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

5

NOTE 3 – GOING CONCERN

 

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2021, it had excess liabilities over assets of $937,168  These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company requires significant cash to launch its business and reduce its payable.  Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.  If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

 

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.


NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.


We expect to generate revenue from home care service providers that are funded by the U.S. Government.  The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.


Earnings per Share

 

Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2021 and 2020, the Company does not have any common share equivalents outstanding.

 

6

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $1,016 and $2,329 and $504 and $4,167, respectively.


Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6).


Related Party Advances

 

The Company’s former Chief Financial Officer (“CFO”) has historically advanced the Company monies for operating expenses; Advances during the nine-month period December 31, 2021 and 2020 were $455 and $0, respectively.  The related party advances totaled $131,447 and $130,992 as of December 31, 2021 and March 31, 2021, respectively.  The advances are due on demand.  The related party advances accrue interest at ten (10) percent per annum.  Repayment is due no later than June 30, 2023.  Interest expense was $9,879 and $9,869 during the nine-month periods ended December 31, 2021 and 2020, respectively.


Note Payables to Shareholders

 

As at December 31, 2021 and March 31, 2021, the Company had various promissory notes with total outstanding principal balances of $468,607 and $374,271, respectively, due to a shareholder of the Company.  These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2022 to December 30, 2023.

 

On April 15, 2021, one note to a shareholder that was originally due on April 15, 2021 with a principal amount of approximately $72,000 ($90,000 Canadian Funds) was reissued in the principal amount of approximately $86,000 ($108,000 Canadian Funds) which included the original principal amount plus interest accrued as at April 15, 2021 in the amount of approximately $14,000 ($18,000 Canadian Funds).  Repayment of the note is due no later than April 15, 2023. On October 11, 2021 one note to a shareholder that was originally due on October 11, 2021 with a principal amount of $10,000 was reissued in the principal amount of $12,000 which included the original principal plus interest accrued as at October 11, 2021 in the amount of $2,000.  Repayment of the note is due no later than October 11, 2023. On October 21, 2021, one note to a shareholder that was originally due on October 21, 2021 with a principal amount of $30,000 was reissued in the principal amount of $36,000 which included the original principal plus interest accrued as at October 21, 2021 in the amount of $6,000.  Repayment of the note is due no later than October 21, 2023. On October 25, 2021, one note to a shareholder that was originally due on October 25, 2021 with a principal amount of $24,500 was reissued in the principal amount of $29,400 which included the original principal plus interest accrued as at October 25, 2021 in the amount of $4,900.  Repayment of the note is due no later than October 25, 2023. On December 9, 2021, one note to a shareholder that was originally due on December 9, 2021 with a principal amount of approximately $4,000 ($5,000 Canadian Funds) was reissued in the principal amount of approximately $5,000 ($6,000 Canadian Funds) which included the original principal plus interest accrued as at December 9, 2021 in the amount of approximately $758 ($1,000 Canadian Funds).  Repayment of the note is due no later than December 9, 2023.

 

7

During the nine-month period ended December 31, 2021, a shareholder was issued additional eight (8) promissory notes totaling $67,082 ($86,500 Canadian Funds).  These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue.


Accrued interest was $42,676 and $33,132 as of December 31, 2021 and March 31, 2021, respectively, which is included in other accrued liabilities.


NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

 

On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.  

 

The Technology Platforms include but are not limited to:

 

A.

Proteomic research platforms which include proprietary blends.
 

B.

Combination design Techniques
 

C.

Patent Pending Proprietary Blends
 

D.

Patent Pending Formulas
 

E.

Trademarks and all pending Trademarks
 

F.

510K USA FDA, information and Know-how for application
 

G.

All Clinical trials, (Right to use)
 

H.

CE mark (International)
 

I.

Regenerex Library formula incorporated in the Wound Healing Technology.
 

J.

Wound Healing Technology QBX
 

K.

Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.


Products:

 

1.

Xcellderma over the counter product.
 

2.

Accelerex, combination product as a drug device.
 

3.

Accelerex in a tube.

 

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. 

 

See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement.  

 

8

NOTE 8 – STOCKHOLDERS’ DEFICIT

 

During the three months ended December 31, 2021, Irene Getty, who resigned as a member of the Board of Directors, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Gregory Pilant and Deborah Pilant upon their appointment as Directors and Officers of the Company.  Irene Getty continues to be the Chief Financial Officer of the Company. Irene Getty was a significant shareholder owning more than 10% of the shares outstanding at the time. The Company recognized stock-based compensation of $45,000 within general and administrative expenses in the accompanying statement of operations related to this transfer of shares.

 

See Note 6 for shares issued in connection with the Asset Purchase Agreement.


NOTE 9 – SUBSEQUENT EVENTS

 

On January 20, 2022, a note to a shareholder that was originally due on January 20, 2022 with a principal amount of approximately $8,000 ($10,000 Canadian Funds) was reissued in the principal amount of approximately $10,000 ($12,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 20, 2022 in the approximate amount of $2,000 ($2,000 Canadian Funds).  Repayment of the note is due no later than January 20, 2024.


On January 31, 2022, a note to a shareholder that was originally due on January 31, 2022 with a principal amount of approximately $53,000 ($70,000 Canadian Funds) was reissued in the principal amount of approximately $66,000 ($84,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 31, 2022 in the approximate amount of $11,000 ($14,000 Canadian Funds).  Repayment of the note is due no later than January 31, 2024.

 

9

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

In this Quarterly Report, “Company,” “our company,” “us,” and “our” refer to Regenerex Pharma, Inc., unless the context requires otherwise.

 

Forward-Looking Statements

 

The following information contains certain forward-looking statements. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “could,” “expect,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

 

Estimated COVID-19 impacts and uncertainties

COVID-19 has severely impacted, and is expected to continue to impact, the economies of the U.S. and other countries around the world COVID-19 has created significant public health concerns as well as significant volatility, uncertainty and economic disruption in every region in which we operate, all of which have adversely affected and may continue to adversely affect our industries and our business operations. Further, financial and credit markets have experienced and may again experience volatility.

 

Beginning in our first fiscal quarter of 2020, the novel coronavirus known as “COVID-19" began to spread throughout the world, resulting in a global pandemic. The pandemic triggered a significant downturn in global commerce as early as February 2020 and the challenging market conditions have continued throughout the second half of fiscal 2020 through 2021 and into the first half of fiscal 2022, and may continue for an extended period of time.

 

COVID-19 continued to affect global economic conditions during the nine months ended December 31, 2021. The Company expects this will continue in the Company’s fourth quarter. The situation surrounding COVID-19 remains fluid, and we are actively managing our response in collaboration with team members and business partners and assessing potential impacts to our financial position and operating results, as well as developments in our business.

 

Discontinued Operations and New Developments


The business of Regenerex Pharma, Inc. (formerly Peptide Technologies, Inc.), (the “Company”), had been to develop and market skincare products.  The Company was doing business as Eternelle Skincare Products.  The Company, was, using proprietary peptide / collagen blends, and was developing a number of skincare products that demonstrated strong efficacy in providing youthful, healthy skin and significant anti-aging benefits to both women and men.  These objectives have not been realized, and the Company has abandoned its efforts in this area.

 

On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.

10

Business of Issuer

 

The business of Regenerex Pharma, Inc., (the “Company” or “Regenerex Pharma,”), is to develop and market Woundcare Healing products.  The Company has three technologies for different types of wound conditions;

 

  • The first is for closing chronic wounds,
  • the second is for accelerating closure of acute or surgical wounds, and
  • the third solves the issue on contamination of all types of wounds including the destruction of biofilms.  

 

The current product technology provides the Company a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. and global markets.  

 

Products:

 

  1. Xcellderma OTC - Liquid Bandage Skin Protectant Xcellderma™ products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx™ the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).

 

  2. Accelerex Sterile Wound Cream - The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx. Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company’s broadly-enabling technology was discovered from oak bark extract and referred to as QBx™.

 

  3. Accelerex Impregnated Sterile Wound Dressing - For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination device that blends the benefits of a wound dressing with two drug components. Provides 3 modes of action to help treat acute and chronic wounds: Protective dressing, moisturizing ointment and 2 drug components: rubidium chloride and potassium chloride

 

QBx™ contributes to setting up a suitable environment to allow wounds to close.  Other than the products marketed by the Company, there are no products currently available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases.  Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids, but these dressings do not impact the cellular environment with simple gauze and gauze-like dressings to cover and protect the wound. 

 

Our products have shown to be very effective in healing chronic wounds in multiple clinical evaluations, with 63% to 94% of wounds demonstrating closure.  All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close. 

 

Wounds that do not heal remain open and are at risk for infection.  The lack of healing ultimately could lead to amputation, severe medical complications, and in some cases, death.  Closing wounds is a paramount concern to health care professionals and patients alike.

 

Chronic wounds impose significant costs to the US economy.  Chronic wounds are a growing issue in the United States, causing immense patient pain and suffering as well as substantial economic and social cost.  Although precise information on the prevalence of chronic wounds in the US is unavailable, it is estimated that, as of 2017, there were more than 6.2 million Americans suffering from chronic wounds.  Chronic wounds are generally defined as wounds that have not healed after ninety days of consistent clinical treatment, and include diabetic foot ulcers, pressure ulcers (bedsores), and venous stasis ulcers, however this does not include acute wounds.

11

The most common chronic wounds are diabetic foot ulcers and pressure ulcers.  The increasing number of Americans with diabetes and obesity we well as the aging population will likely cause the number of individuals with chronic wounds to continue to rise.  In addition to the immeasurable human benefits of improving treatment outcomes, there would be substantial economic effect.  The costs of medical treatment could be expected to decrease, and, as patients are able to return to work sooner, productivity would increase.

 

Due to the staggering costs associated with chronic wounds in the US, the Affordable Healthcare Act (AHA) is changing how the entire wound care system is reimbursed in the US. Now all four markets segments: hospital, nursing homes, home health, and general wound care clinics are all on paid on a “pay for performance basis.”  These cost pressures in the healthcare system are a major issue in the wound care market, with the US government and payors seeking new approaches that address cost constraints and product performance.  Home health is now paid on a “diagnostic code” for the wound in single payments removing the risk from the Payee to the Payer.  The Company’s first markets will be those segments that are totally “at risk” for single payments to close the wounds.  Today, the fastest growing segment in the US wound market is Home Health and Nursing Homes due to the aging population. 


The Company has purchased proprietary wound care formulations, and the Company is using internationally recognized experts in the manufacturing of specialized, professional quality products that meet the demands of the USA markets.  We expect to launch our sales initiative during the Company’s second quarter of 2022.

 

Financial Results and Trends

 

Results of Operations for the Nine months Ended December 31, 2021 and 2020

 

At present, the Company has $0 and $378 revenue during the nine months ended December 31, 2021 and 2020, respectively.  Net loss increased from $69,272 for the nine months ended December 31, 2020 to $147,142 for the nine months ended December 31, 2021 due to higher stock-based compensation, accounting fees, legal fees, sales and marketing costs and interest expense offset by lesser decrease in office supplies.

 

Liquidity and Capital Resources

 

The Company requires significant cash to launch its business and reduce its payables.  Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. The Company’s primary sources of liquidity and capital resources have been notes payable, which are not sufficient prospectively.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  If the Company is unable to raise additional capital in the near future or meet financing requirements, the Company may need to curtail or alter its plan of operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

 

Cash Flow

 

The following table summarizes, for the periods indicated, selected items in our condensed Statements of Cash Flows:

 

   

Nine months Ended

  
   

December  31,

  
   

2021

    

2020

  

Net cash (used in) provided by:

                

Operating activities

  

$

(63,050

)

  

$

(37,552

)

Investing activities

  

$

(8,600

)

  

$

—

  

Financing activities

  

$

67,537

    

$

33,813

  

12

Operating Activities

 

Cash used in operating activities was $63,050 and $37,552 for the nine months ended December 31, 2021 and 2020, respectively. The increase in cash used in operating activities was primarily due to an increase in net loss offset by a lesser increase in accounts payables.

 

Investing Activities

 

Cash used in investing activities was $8,600 and $0 for the nine months ended December 31, 2021 and 2020.  The increase in cash used in investing activities was due to an increase in Website Development.

 

Financing Activities

 

Cash provided by financing activities was $67,537 and $33,813 for the nine months ended December 31, 2021 and 2020, respectively. The increase in cash provided by financing activities was primarily due to an increase in notes payables issued to shareholders.

 

Off-Balance Sheet Arrangements

 

None.

13

WHERE YOU CAN FIND MORE INFORMATION

 

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Registration Statement on Form 10-12G, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We had no material changes in market risk from those described in “Item 2—Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K.

 

ITEM 4. CONTROLS AND PROCEDURES

 

This report includes the certification of our Chief Executive Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations revered to in those certifications.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

 

Under the supervision and with the participation of management, including the principal executive officer and principal financial officer, the Company conducted an evaluation of the effectiveness of internal control over financial reporting. This assessment was based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation under the framework in Internal Control – Integrated Framework, management concluded that the Company maintained effective internal control over financial reporting as of December 31, 2021, as such term is defined in Exchange Act Rule 13a-15(f).

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives.

 

As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer need to carry out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021.

 

Management’s Report on Internal Control over Financial Reporting

 

Our Chief Executive Officer and the Chief Financial Officer are responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of our internal control over financial reporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. GAAP. Internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (c) provide reasonable assurance that receipts and expenditures are being made only in accordance with appropriate authorization of management and the Board of Directors, and (d) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

14

In connection with the preparation of this Quarterly Report on Form 10-Q for the quarter ended December 31, 2021, our Chief Executive Officer and Chief Financial Officer have concluded that our internal controls and procedures over financial reporting were effective as of December 31, 2021.

 

Inherent Limitations on Internal Controls

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Limitations inherent in any control system include the following:

 

  ● Judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes;
     
  ● Controls can be circumvented by individuals, acting alone or in collusion with others, or by management override;
     
  ● The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;
     
  ● Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures; and
     
  ● The design of a control system must reflect the fact that resources are constrained, and the benefits of controls must be considered relative to their costs.

 

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

15

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

As of December 31, 2021, the Company is not involved in any material litigation.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

 

During the nine months ended December 31, 2021, Regenerex did not sell any unregistered equity securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

There is no information with respect to which information is not otherwise called for by this form.

  

ITEM 6. EXHIBITS

 

Exhibits

 

3.0 Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.
   
3.1 Amended Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.
   
3.2 Amended Articles of Incorporation.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.
   
3.3 Corporate Bylaws.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.
   
10.1 Advance from Baxter Koehn to Regenerex Pharma, Inc.  Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.
   
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
   
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
   
32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act
   
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

16

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant

Regenerex Pharma, Inc.

 

 

Date: February 2, 2022

By:

/s/ Bruce Sellars

 

Bruce Sellars

 

Chief Executive Officer
EX-31.1 2 exhibit31-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 31.1

Exhibit 31.1

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending December 31, 2021


I, Bruce Sellars, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  e. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  f. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant

Regenerex Pharma, Inc.
   

Date: February 2, 2022

By:

/s/ Bruce Sellars
 

Bruce Sellars
 

Chief Executive Officer (Principal Executive Officer)
EX-31.2 3 exhibit31-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 31.2

Exhibit 31.2

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending December 31, 2021

 

I, Irene Getty, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Registrant

Regenerex Pharma, Inc.
   

Date: February 2, 2022

By:

/s/ Irene Getty
 

Irene Getty
 

Chief Financial Officer (Principal Financial Officer)
EX-32.1 4 exhibit32-1.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 32.1

Exhibit 32.1

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Regenerex Pharma, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Bruce Sellars, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant

Regenerex Pharma, Inc.
   

Date : February 2, 2022

By:

/s/ Bruce Sellars
 

Bruce Sellars
 

Chief Executive Officer (Principal Executive Officer)
EX-32.2 5 exhibit32-2.htm CERTIFICATION Filed by Avantafile.com - Peptide Technologies, Inc. - Exhibit 32.2

Exhibit 32.2

 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Regenerex Pharma, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Irene Getty, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Registrant

Regenerex Pharma, Inc.
   

Date:  February 2, 2022

By:

/s/ Irene Getty
 

Irene Getty
 

Chief Financial Officer (Principal Financial Officer)
GRAPHIC 6 regenerexlogo.gif begin 644 regenerexlogo.gif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end EX-101.SCH 7 rep1357878-20211231.xsd SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DIFICIT link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rep1357878-20211231_cal.xml CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 rep1357878-20211231_def.xml DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 rep1357878-20211231_lab.xml LABELS LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Purchase Intellectual Property [Member] Related Party [Axis] Chief Executive Officer [Member] Note Payable To Shareholder [Member] Debt Instrument [Axis] April 15 Note 2021 [Member] October 11 Note 2021 [Member] October 21 Note 2021 [Member] October 25 Note 2021 [Member] December 9 Note 2021 [Member] Promissory Note 1 [Member] Promissory Note 2 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name Statement of Financial Position [Abstract] ASSETS Current Assets Cash and equivalents Prepaid expenses Total Current Assets Website, net of accumulated amortization of $21,974 and $19,645, respectively Total Assets Current Liabilities Accounts payable Related party advances Accrued compensation Other accrued liabilities Current portion of notes payable to shareholder Total Current Liabilities Notes payable to shareholder, net of current portion Total Liabilities Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively  Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Accumulated Amortization, Website Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Sales Cost of Sales Gross Loss Operating Expenses General and administrative Sales and marketing Total Operating Expenses Operating Loss Other Income (Expense) Interest expense Foreign currency gain (loss) Total Other Income (Expense) Net Loss Basic and Diluted Loss per Common Share Weighted Average Number of Common Shares Outstanding Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net loss Adjustments to reconcile net loss to cash flows used in operating activities: Depreciation Foreign currency adjustments Stock-based compensation Changes in operating assets and liabilities: Inventories Prepaid expenses Accounts payable and accrued liabilities Net cash used in operating activities Cash Flows from Investing Activities: Website Net cash used in investing activities Cash Flows from Financing Activities: Related party advances Proceeds from notes payable to shareholder Net cash provided by financing activities Decrease in cash and equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Income Taxes Interest Non-Cash Investing and Financing Activities: Accrued interest converted into note payable to shareholder Statement [Table] Statement [Line Items] Balance at September 30, 2021 Common Stock, Shares, Outstanding, Beginning Balance Balance at December 31, 2021 Common Stock, Shares, Outstanding, Ending Balance Common stock issued for purchase of intellectual property Common stock issued for purchase of intellectual property Stock-based compensation Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ DEFICIT Subsequent Events [Abstract] SUBSEQUENT EVENTS Revenue Recognition Earnings per Share Website Recent Accounting Pronouncements Entity Incorporation, Date of Incorporation Shares, Issued Asset Acquisition, Contingent Consideration, Liability Asset Acquisition, Contingent Consideration, Liability [Abstract] Stockholders' Equity Attributable to Parent Amortization of Intangible Assets Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Advances Interest Expense, Related Party Long-term Debt, Fair Value Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Maturity Date Range, Start Debt Instrument, Maturity Date Range, End Debt Instrument, Face Amount Debt Instrument, Maturity Date Notes Payable Debt Instrument, Maturity Date, Description Accrued Interest Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Business Combination, Contingent Consideration Arrangements, Description Share-based Payment Arrangement, Noncash Expense Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Debt Instrument, Issuance Date Liabilities Operating Expenses [Default Label] Operating Income (Loss) Interest Expense Increase (Decrease) in Prepaid Expense Payments for Software Proceeds from Related Party Debt Net Cash Provided by (Used in) Financing Activities StockIssuedDuringPeriodPurchaseOfIntellectualProperty Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture EX-101.PRE 11 rep1357878-20211231_pre.xml PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - shares
 9 Months Ended
Dec. 31, 2021
Feb. 02, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --03-31  
Entity File Number 000-53230  
Entity Registrant Name REGENEREX PHARMA, INC.  
Entity Central Index Key 0001357878  
Entity Tax Identification Number 98-0479983  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 5348 Vegas Drive #177  
Entity Address, City or Town Las Vegas  
Entity Address, State or Province NV  
Entity Address, Postal Zip Code 89108  
City Area Code (702)  
Local Phone Number 273-3772  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   277,112,660
Entity Information, Former Legal or Registered Name Peptide Technologies, Inc.  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
BALANCE SHEETS - USD ($)
Dec. 31, 2021
Mar. 31, 2021
Current Assets    
Cash and equivalents $ 2,789 $ 6,902
Prepaid expenses 1,213
Total Current Assets 2,789 8,115
Website, net of accumulated amortization of $21,974 and $19,645, respectively 8,626 2,355
Total Assets 11,415 10,470
Current Liabilities    
Accounts payable 47,813 48,038
Related party advances 131,447 130,992
Accrued compensation 221,192 221,192
Other accrued liabilities 79,524 71,003
Current portion of notes payable to shareholder 118,853 150,094
Total Current Liabilities 598,829 621,319
Notes payable to shareholder, net of current portion 349,754 224,177
Total Liabilities 948,583 845,496
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively  277,113 127,113
Additional paid-in capital 671,963 776,963
Accumulated deficit (1,886,244) (1,739,102)
Total Stockholders’ Deficit (937,168) (835,026)
Total Liabilities and Stockholders’ Deficit $ 11,415 $ 10,470
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
BALANCE SHEETS (Parenthetical) - USD ($)
Dec. 31, 2021
Mar. 31, 2021
Statement of Financial Position [Abstract]    
Accumulated Amortization, Website $ 21,974 $ 19,645
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares Authorized 675,000,000 675,000,000
Common Stock, Shares, Issued 277,112,660 127,112,660
Common Stock, Shares, Outstanding 277,112,660 127,112,660
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]        
Sales $ 181 $ 378
Cost of Sales 364 406
Gross Loss (183) (28)
Operating Expenses        
General and administrative 62,385 12,103 100,192 33,229
Sales and marketing 612 1,966 3,303 3,056
Total Operating Expenses 62,997 14,069 103,495 36,285
Operating Loss (62,997) (14,252) (103,495) (36,313)
Other Income (Expense)        
Interest expense (14,548) (11,203) (44,130) (31,335)
Foreign currency gain (loss) (1,889) (8,228) 483 (1,624)
Total Other Income (Expense) (16,437) (19,431) (43,647) (32,959)
Net Loss $ (79,434) $ (33,683) $ (147,142) $ (69,272)
Basic and Diluted Loss per Common Share $ (0.00) $ (0.00) $ (0.00) $ (0.00)
Weighted Average Number of Common Shares Outstanding 203,743,095 127,112,660 152,749,024 127,112,660
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities:    
Net loss $ (147,142) $ (69,272)
Adjustments to reconcile net loss to cash flows used in operating activities:    
Depreciation 2,329 4,167
Foreign currency adjustments (483) 1,624
Stock-based compensation 45,000
Changes in operating assets and liabilities:    
Inventories 406
Prepaid expenses 1,213 (1,645)
Accounts payable and accrued liabilities 36,033 27,168
Net cash used in operating activities (63,050) (37,552)
Cash Flows from Investing Activities:    
Website (8,600)
Net cash used in investing activities (8,600)
Cash Flows from Financing Activities:    
Related party advances 455
Proceeds from notes payable to shareholder 67,082 33,813
Net cash provided by financing activities 67,537 33,813
Decrease in cash and equivalents (4,113) (3,739)
Cash and cash equivalents, beginning of period 6,902 5,460
Cash and cash equivalents, end of period 2,789 1,721
Income Taxes
Interest
Non-Cash Investing and Financing Activities:    
Accrued interest converted into note payable to shareholder $ 27,254
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
STATEMENTS OF STOCKHOLDERS' DIFICIT - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Balance at September 30, 2021 $ (902,734) $ (516,863) $ (835,026) $ (481,274) $ (835,026) $ (481,274)
Common Stock, Shares, Outstanding, Beginning Balance     127,112,660   127,112,660  
Net Loss (79,434) (33,683) $ (67,708) (35,589) $ (147,142) (69,272)
Balance at December 31, 2021 $ (937,168) (550,546) (902,734) (516,863) $ (937,168) (550,546)
Common Stock, Shares, Outstanding, Ending Balance 277,112,660       277,112,660  
Common stock issued for purchase of intellectual property          
Stock-based compensation 45,000          
Common Stock [Member]            
Balance at September 30, 2021 $ 127,113 $ 127,113 $ 127,113 $ 127,113 $ 127,113 $ 127,113
Common Stock, Shares, Outstanding, Beginning Balance 127,112,660 127,112,660 127,112,660 127,112,660 127,112,660 127,112,660
Net Loss    
Balance at December 31, 2021 $ 277,113 $ 127,113 $ 127,113 $ 127,113 $ 277,113 $ 127,113
Common Stock, Shares, Outstanding, Ending Balance 277,112,660 127,112,660 127,112,660 127,112,660 277,112,660 127,112,660
Common stock issued for purchase of intellectual property 150,000          
Common stock issued for purchase of intellectual property 150,000,000          
Stock-based compensation          
Additional Paid-in Capital [Member]            
Balance at September 30, 2021 $ 776,963 $ 776,963 $ 776,963 $ 776,963 $ 776,963 $ 776,963
Net Loss    
Balance at December 31, 2021 $ 671,963 776,963 776,963 776,963 671,963 776,963
Common stock issued for purchase of intellectual property (150,000)          
Stock-based compensation 45,000          
Retained Earnings [Member]            
Balance at September 30, 2021 $ (1,806,810) (1,420,939) (1,739,102) (1,385,350) (1,739,102) (1,385,350)
Net Loss (79,434) (33,683) (67,708) (35,589)    
Balance at December 31, 2021 $ (1,886,244) $ (1,454,622) $ (1,806,810) $ (1,420,939) $ (1,886,244) $ (1,454,622)
Common stock issued for purchase of intellectual property          
Stock-based compensation          
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
NATURE OF OPERATIONS
 9 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

NOTE 1 – NATURE OF OPERATIONS

 

Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.  The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced.  The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.


On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.


Management has decided to focus on this new business development.

 

Risks and Uncertainties 


Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.


The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.

 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS
 9 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

 

Operating results for the nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2021 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2021 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
GOING CONCERN
 9 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 3 – GOING CONCERN

 

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2021, it had excess liabilities over assets of $937,168  These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company requires significant cash to launch its business and reduce its payable.  Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.  If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

 

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.


We expect to generate revenue from home care service providers that are funded by the U.S. Government.  The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.


Earnings per Share

 

Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2021 and 2020, the Company does not have any common share equivalents outstanding.

 

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $1,016 and $2,329 and $504 and $4,167, respectively.


Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
RELATED PARTY TRANSACTIONS
 9 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 5 – RELATED PARTY TRANSACTIONS

 

The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6).


Related Party Advances

 

The Company’s former Chief Financial Officer (“CFO”) has historically advanced the Company monies for operating expenses; Advances during the nine-month period December 31, 2021 and 2020 were $455 and $0, respectively.  The related party advances totaled $131,447 and $130,992 as of December 31, 2021 and March 31, 2021, respectively.  The advances are due on demand.  The related party advances accrue interest at ten (10) percent per annum.  Repayment is due no later than June 30, 2023.  Interest expense was $9,879 and $9,869 during the nine-month periods ended December 31, 2021 and 2020, respectively.


Note Payables to Shareholders

 

As at December 31, 2021 and March 31, 2021, the Company had various promissory notes with total outstanding principal balances of $468,607 and $374,271, respectively, due to a shareholder of the Company.  These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2022 to December 30, 2023.

 

On April 15, 2021, one note to a shareholder that was originally due on April 15, 2021 with a principal amount of approximately $72,000 ($90,000 Canadian Funds) was reissued in the principal amount of approximately $86,000 ($108,000 Canadian Funds) which included the original principal amount plus interest accrued as at April 15, 2021 in the amount of approximately $14,000 ($18,000 Canadian Funds).  Repayment of the note is due no later than April 15, 2023. On October 11, 2021 one note to a shareholder that was originally due on October 11, 2021 with a principal amount of $10,000 was reissued in the principal amount of $12,000 which included the original principal plus interest accrued as at October 11, 2021 in the amount of $2,000.  Repayment of the note is due no later than October 11, 2023. On October 21, 2021, one note to a shareholder that was originally due on October 21, 2021 with a principal amount of $30,000 was reissued in the principal amount of $36,000 which included the original principal plus interest accrued as at October 21, 2021 in the amount of $6,000.  Repayment of the note is due no later than October 21, 2023. On October 25, 2021, one note to a shareholder that was originally due on October 25, 2021 with a principal amount of $24,500 was reissued in the principal amount of $29,400 which included the original principal plus interest accrued as at October 25, 2021 in the amount of $4,900.  Repayment of the note is due no later than October 25, 2023. On December 9, 2021, one note to a shareholder that was originally due on December 9, 2021 with a principal amount of approximately $4,000 ($5,000 Canadian Funds) was reissued in the principal amount of approximately $5,000 ($6,000 Canadian Funds) which included the original principal plus interest accrued as at December 9, 2021 in the amount of approximately $758 ($1,000 Canadian Funds).  Repayment of the note is due no later than December 9, 2023.

 

During the nine-month period ended December 31, 2021, a shareholder was issued additional eight (8) promissory notes totaling $67,082 ($86,500 Canadian Funds).  These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue.


Accrued interest was $42,676 and $33,132 as of December 31, 2021 and March 31, 2021, respectively, which is included in other accrued liabilities.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
 9 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

 

On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.  

 

The Technology Platforms include but are not limited to:

 

A.

Proteomic research platforms which include proprietary blends.
 

B.

Combination design Techniques
 

C.

Patent Pending Proprietary Blends
 

D.

Patent Pending Formulas
 

E.

Trademarks and all pending Trademarks
 

F.

510K USA FDA, information and Know-how for application
 

G.

All Clinical trials, (Right to use)
 

H.

CE mark (International)
 

I.

Regenerex Library formula incorporated in the Wound Healing Technology.
 

J.

Wound Healing Technology QBX
 

K.

Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.


Products:

 

1.

Xcellderma over the counter product.
 

2.

Accelerex, combination product as a drug device.
 

3.

Accelerex in a tube.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

 

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. 

 

See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement.  

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS’ DEFICIT
 9 Months Ended
Dec. 31, 2021
Equity [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 8 – STOCKHOLDERS’ DEFICIT

 

During the three months ended December 31, 2021, Irene Getty, who resigned as a member of the Board of Directors, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Gregory Pilant and Deborah Pilant upon their appointment as Directors and Officers of the Company.  Irene Getty continues to be the Chief Financial Officer of the Company. Irene Getty was a significant shareholder owning more than 10% of the shares outstanding at the time. The Company recognized stock-based compensation of $45,000 within general and administrative expenses in the accompanying statement of operations related to this transfer of shares.

 

See Note 6 for shares issued in connection with the Asset Purchase Agreement.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSEQUENT EVENTS
 9 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

 

On January 20, 2022, a note to a shareholder that was originally due on January 20, 2022 with a principal amount of approximately $8,000 ($10,000 Canadian Funds) was reissued in the principal amount of approximately $10,000 ($12,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 20, 2022 in the approximate amount of $2,000 ($2,000 Canadian Funds).  Repayment of the note is due no later than January 20, 2024.


On January 31, 2022, a note to a shareholder that was originally due on January 31, 2022 with a principal amount of approximately $53,000 ($70,000 Canadian Funds) was reissued in the principal amount of approximately $66,000 ($84,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 31, 2022 in the approximate amount of $11,000 ($14,000 Canadian Funds).  Repayment of the note is due no later than January 31, 2024.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Revenue Recognition

Revenue Recognition

 

The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.


We expect to generate revenue from home care service providers that are funded by the U.S. Government.  The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share

Earnings per Share

 

Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2021 and 2020, the Company does not have any common share equivalents outstanding.

 
Website

Website

 

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $1,016 and $2,329 and $504 and $4,167, respectively.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
NATURE OF OPERATIONS (Details Narrative) - USD ($)
 9 Months Ended
Dec. 31, 2021
Nov. 15, 2021
Entity Incorporation, Date of Incorporation Nov. 18, 2005  
Asset Acquisition, Contingent Consideration, Liability   $ 10,000,000
Purchase Intellectual Property [Member]    
Shares, Issued   150,000,000
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
GOING CONCERN (Details Narrative) - USD ($)
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]            
Stockholders' Equity Attributable to Parent $ 937,168 $ 902,734 $ 835,026 $ 550,546 $ 516,863 $ 481,274
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]        
Amortization of Intangible Assets $ 1,016 $ 2,329 $ 504 $ 4,167
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2021
Related Party Transaction [Line Items]          
Related Party Advances $ 131,447 $ 131,447 $ 131,447   $ 130,992
Interest Expense, Related Party     9,879 $ 9,869  
Debt Instrument, Maturity Date Range, Start   Jan. 20, 2022      
Debt Instrument, Maturity Date Range, End   Dec. 30, 2023      
Notes Payable $ 349,754 $ 349,754 349,754   224,177
Debt Instrument, Maturity Date, Description due twenty-four (24) months after the date of issue        
Accrued Interest $ 42,676 42,676 42,676   33,132
April 15 Note 2021 [Member]          
Related Party Transaction [Line Items]          
Debt Instrument, Face Amount $ 86,000 86,000 86,000    
Debt Instrument, Maturity Date Apr. 15, 2023        
October 11 Note 2021 [Member]          
Related Party Transaction [Line Items]          
Debt Instrument, Face Amount $ 12,000 12,000 12,000    
Debt Instrument, Maturity Date Oct. 11, 2023        
October 21 Note 2021 [Member]          
Related Party Transaction [Line Items]          
Debt Instrument, Face Amount $ 36,000 36,000 36,000    
Debt Instrument, Maturity Date Oct. 21, 2023        
October 25 Note 2021 [Member]          
Related Party Transaction [Line Items]          
Debt Instrument, Face Amount $ 29,400 29,400 29,400    
Debt Instrument, Maturity Date Oct. 25, 2023        
December 9 Note 2021 [Member]          
Related Party Transaction [Line Items]          
Debt Instrument, Face Amount $ 5,000 5,000 5,000    
Debt Instrument, Maturity Date Dec. 09, 2023        
Chief Executive Officer [Member]          
Related Party Transaction [Line Items]          
Related Party Advances $ 455 455 455 $ 0  
Note Payable To Shareholder [Member]          
Related Party Transaction [Line Items]          
Long-term Debt, Fair Value $ 468,607 $ 468,607 $ 468,607   $ 374,271
Debt Instrument, Interest Rate, Stated Percentage 10.00% 10.00% 10.00%   10.00%
Notes Payable $ 67,082 $ 67,082 $ 67,082    
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)
 1 Months Ended
Nov. 15, 2021
shares
Goodwill and Intangible Assets Disclosure [Abstract]  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 150,000,000
Business Combination, Contingent Consideration Arrangements, Description up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Share-based Payment Arrangement, Noncash Expense $ 45,000
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 1 Months Ended
Jan. 31, 2022
Jan. 20, 2022
Promissory Note 1 [Member]    
Short-term Debt [Line Items]    
Debt Instrument, Issuance Date   Jan. 20, 2022
Debt Instrument, Face Amount   $ 10,000
Debt Instrument, Maturity Date   Jan. 20, 2024
Promissory Note 2 [Member]    
Short-term Debt [Line Items]    
Debt Instrument, Issuance Date Jan. 31, 2022  
Debt Instrument, Face Amount $ 66,000  
Debt Instrument, Maturity Date Jan. 31, 2024  
XML 35 ixform10q_htm.xml IDEA: XBRL DOCUMENT 0001357878 2021-04-01 2021-12-31 0001357878 2022-02-02 0001357878 2021-12-31 0001357878 2021-03-31 0001357878 2021-10-01 2021-12-31 0001357878 2020-10-01 2020-12-31 0001357878 2020-04-01 2020-12-31 0001357878 2020-03-31 0001357878 2020-12-31 0001357878 us-gaap:CommonStockMember 2020-03-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001357878 us-gaap:RetainedEarningsMember 2020-03-31 0001357878 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-09-30 0001357878 us-gaap:RetainedEarningsMember 2020-04-01 2020-09-30 0001357878 2020-04-01 2020-09-30 0001357878 us-gaap:CommonStockMember 2020-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001357878 us-gaap:RetainedEarningsMember 2020-09-30 0001357878 2020-09-30 0001357878 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001357878 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001357878 us-gaap:CommonStockMember 2020-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001357878 us-gaap:RetainedEarningsMember 2020-12-31 0001357878 us-gaap:CommonStockMember 2021-03-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001357878 us-gaap:RetainedEarningsMember 2021-03-31 0001357878 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-09-30 0001357878 us-gaap:RetainedEarningsMember 2021-04-01 2021-09-30 0001357878 2021-04-01 2021-09-30 0001357878 us-gaap:CommonStockMember 2021-09-30 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001357878 us-gaap:RetainedEarningsMember 2021-09-30 0001357878 2021-09-30 0001357878 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001357878 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001357878 us-gaap:CommonStockMember 2021-12-31 0001357878 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001357878 us-gaap:RetainedEarningsMember 2021-12-31 0001357878 rep1357878:PurchaseIntellectualPropertyMember 2021-11-15 0001357878 2021-11-15 0001357878 2021-11-01 2021-11-15 0001357878 2021-01-01 2021-12-31 0001357878 2020-01-01 2020-12-31 0001357878 srt:ChiefExecutiveOfficerMember 2021-12-31 0001357878 srt:ChiefExecutiveOfficerMember 2020-12-31 0001357878 rep1357878:NotePayableToShareholderMember 2021-12-31 0001357878 rep1357878:NotePayableToShareholderMember 2021-03-31 0001357878 rep1357878:April15Note2021Member 2021-12-31 0001357878 rep1357878:April15Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October11Note2021Member 2021-12-31 0001357878 rep1357878:October11Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October21Note2021Member 2021-12-31 0001357878 rep1357878:October21Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:October25Note2021Member 2021-12-31 0001357878 rep1357878:October25Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:December9Note2021Member 2021-12-31 0001357878 rep1357878:December9Note2021Member 2021-10-01 2021-12-31 0001357878 rep1357878:PromissoryNote1Member 2022-01-01 2022-01-20 0001357878 rep1357878:PromissoryNote1Member 2022-01-20 0001357878 rep1357878:PromissoryNote2Member 2022-01-01 2022-01-31 0001357878 rep1357878:PromissoryNote2Member 2022-01-31 iso4217:USD shares iso4217:USD shares pure 0001357878 false 2021 Q3 --03-31 10-Q true 2021-12-31 false 000-53230 REGENEREX PHARMA, INC. NV 98-0479983 5348 Vegas Drive #177 Las Vegas NV 89108 (702) 273-3772 Peptide Technologies, Inc. Yes Yes Non-accelerated Filer true true false false 277112660 2789 6902 1213 2789 8115 21974 19645 8626 2355 11415 10470 47813 48038 131447 130992 221192 221192 79524 71003 118853 150094 598829 621319 349754 224177 948583 845496 0.001 0.001 675000000 675000000 277112660 277112660 127112660 127112660 277113 127113 671963 776963 -1886244 -1739102 -937168 -835026 11415 10470 181 378 364 406 -183 -28 62385 12103 100192 33229 612 1966 3303 3056 62997 14069 103495 36285 -62997 -14252 -103495 -36313 14548 11203 44130 31335 -1889 -8228 483 -1624 -16437 -19431 -43647 -32959 -79434 -33683 -147142 -69272 -0.00 -0.00 -0.00 -0.00 203743095 127112660 152749024 127112660 -147142 -69272 2329 4167 -483 1624 45000 406 1213 -1645 36033 27168 -63050 -37552 8600 -8600 455 67082 33813 67537 33813 -4113 -3739 6902 5460 2789 1721 27254 127112660 127113 776963 -1385350 -481274 -35589 -35589 127112660 127113 776963 -1420939 -516863 127112660 127113 776963 -1420939 -516863 -33683 -33683 127112660 127113 776963 -1454622 -550546 127112660 127113 776963 -1739102 -835026 -67708 -67708 127112660 127113 776963 -1806810 -902734 127112660 127113 776963 -1806810 -902734 150000000 150000 -150000 45000 45000 -79434 -79434 277112660 277113 671963 -1886244 -937168 <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on</span> November 18, 2005<span style="font-size: 10pt">.  The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced.  The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Management has decided to focus on this new business development.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i><i style="font-size: 10pt"> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i><br/></i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> 2005-11-18 150000000 10000000 <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Operating results for the nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2021 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2021 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.</p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_6"/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b style="font-size: 10pt">NOTE 3 – GOING CONCERN</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2021, it had excess liabilities over assets of $937,168  These factors raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company requires significant cash to launch its business and reduce its payable.  Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.  If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> -937168 <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b><i> </i></b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Revenue Recognition</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">We expect to generate revenue from home care service providers that are funded by the U.S. Government.  The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Earnings per Share</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">Earnings per share is reported in accordance with FASB </span><span style="font-size: 10pt">Accounting Standards Codification (“ASC”) </span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">Topic 260 “<i>Earnings per Share</i>” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of </span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">December 31</span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">, 2021 and 2020, the Company does not have any common share equivalents outstanding.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="background-color: #FDFDFD"> </span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="background-color: #FDFDFD"/></p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_7"/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Website</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $</span>1,016<span style="font-size: 10pt"> and $</span>2,329<span style="font-size: 10pt"> and $</span>504<span style="font-size: 10pt"> and $</span>4,167<span style="font-size: 10pt">, respectively.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Recent Accounting Pronouncements</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Revenue Recognition</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">We expect to generate revenue from home care service providers that are funded by the U.S. Government.  The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Earnings per Share</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">Earnings per share is reported in accordance with FASB </span><span style="font-size: 10pt">Accounting Standards Codification (“ASC”) </span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">Topic 260 “<i>Earnings per Share</i>” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of </span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">December 31</span><span style="font-size: 10pt; background-color: rgb(253, 253, 253)">, 2021 and 2020, the Company does not have any common share equivalents outstanding.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="background-color: #FDFDFD"> </span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="background-color: #FDFDFD"/></p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_7"/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Website</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $</span>1,016<span style="font-size: 10pt"> and $</span>2,329<span style="font-size: 10pt"> and $</span>504<span style="font-size: 10pt"> and $</span>4,167<span style="font-size: 10pt">, respectively.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> 1016 2329 504 4167 <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Recent Accounting Pronouncements</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b style="font-size: 10pt">NOTE 5 – RELATED PARTY TRANSACTIONS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6).</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Related Party Advances</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">The Company’s former Chief Financial Officer (“CFO”) has historically advanced the Company monies for operating expenses; Advances during the nine-month period December 31, 2021 and 2020 were $455 and $0, respectively.  The related party advances totaled $</span>131,447<span style="font-size: 10pt"> and $</span>130,992<span style="font-size: 10pt"> as of December 31, 2021 and March 31, 2021, respectively.  The advances are due on demand.  The related party advances accrue interest at ten (10) percent per annum.  Repayment is due no later than June 30, 2023.  Interest expense was $</span>9,879<span style="font-size: 10pt"> and $</span>9,869<span style="font-size: 10pt"> during the nine-month periods ended December 31, 2021 and 2020, respectively.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Note Payables to Shareholders</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">As at December 31, 2021 and March 31, 2021, the Company had various promissory notes with total outstanding principal balances of $468,607 and $374,271, respectively, due to a shareholder of the Company.  These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2022 to December 30, 2023.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On April 15, 2021, one note to a shareholder that was originally due on April 15, 2021 with a principal amount of approximately $72,000 ($90,000 Canadian Funds) was reissued in the principal amount of approximately $86,000 ($108,000 Canadian Funds) which included the original principal amount plus interest accrued as at April 15, 2021 in the amount of approximately $14,000 ($18,000 Canadian Funds).  Repayment of the note is due no later than April 15, 2023. On October 11, 2021 one note to a shareholder that was originally due on October 11, 2021 with a principal amount of $10,000 was reissued in the principal amount of $12,000 which included the original principal plus interest accrued as at October 11, 2021 in the amount of $2,000.  Repayment of the note is due no later than October 11, 2023. On October 21, 2021, one note to a shareholder that was originally due on October 21, 2021 with a principal amount of $30,000 was reissued in the principal amount of $36,000 which included the original principal plus interest accrued as at October 21, 2021 in the amount of $6,000.  Repayment of the note is due no later than October 21, 2023. On October 25, 2021, one note to a shareholder that was originally due on October 25, 2021 with a principal amount of $24,500 was reissued in the principal amount of $29,400 which included the original principal plus interest accrued as at October 25, 2021 in the amount of $4,900.  Repayment of the note is due no later than October 25, 2023. On December 9, 2021, one note to a shareholder that was originally due on December 9, 2021 with a principal amount of approximately $4,000 ($5,000 Canadian Funds) was reissued in the principal amount of approximately $5,000 ($6,000 Canadian Funds) which included the original principal plus interest accrued as at December 9, 2021 in the amount of approximately $758 ($1,000 Canadian Funds).  Repayment of the note is due no later than December 9, 2023.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_8"/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">During the nine-month period ended December 31, 2021, a shareholder was issued additional eight (8) promissory notes totaling $67,082 ($86,500 Canadian Funds).  These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Accrued interest was $42,676 and $33,132 as of December 31, 2021 and March 31, 2021, respectively, which is included in other accrued liabilities.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> 455 0 131447 130992 9879 9869 468607 374271 0.10 0.10 2022-01-20 2023-12-30 86000 2023-04-15 12000 2023-10-11 36000 2023-10-21 29400 2023-10-25 5000 2023-12-09 67082 due twenty-four (24) months after the date of issue 42676 33132 <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 </span><span style="font-size: 10pt">shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.  The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.  </span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Technology Platforms include but are not limited to:</p> <p style="text-align: justify; font-size: 10pt"/> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">A.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Proteomic research platforms which include proprietary blends.</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">B.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Combination design Techniques</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">C.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Patent Pending Proprietary Blends</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">D.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Patent Pending Formulas</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">E.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Trademarks and all pending Trademarks</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">F.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> 510K USA FDA, information and Know-how for application</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">G.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> All Clinical trials, (Right to use)</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">H.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> CE mark (International)</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">I.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Regenerex Library formula incorporated in the Wound Healing Technology.</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">J.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Wound Healing Technology QBX</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">K.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.</p></td> </tr> </table> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Products:</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"/> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">1.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Xcellderma over the counter product.</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">2.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Accelerex, combination product as a drug device.</p></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><p style="margin: 0; font-size: 10pt">3.</p></td> <td style="text-align: justify"><p style="margin: 0; font-size: 10pt"> Accelerex in a tube.</p></td> </tr> </table> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b> </b></p> 150000000 up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 7 – COMMITMENTS AND CONTINGENCIES</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt">The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. </p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement.  </span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_9"/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 8 – STOCKHOLDERS’ DEFICIT</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt">During the three months ended December 31, 2021, Irene Getty, who resigned as a member of the Board of Directors, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Gregory Pilant and Deborah Pilant upon their appointment as Directors and Officers of the Company.  Irene Getty continues to be the Chief Financial Officer of the Company. Irene Getty was a significant shareholder owning more than 10% of the shares outstanding at the time. The Company recognized stock-based compensation of $45,000 within general and administrative expenses in the accompanying statement of operations related to this transfer of shares.</p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p class="MsoNormal" style="margin: 0px; text-align: justify; font-size: 10pt">See Note 6 for shares issued in connection with the Asset Purchase Agreement.<br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> 45000 <p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 9 – SUBSEQUENT EVENTS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On January 20, 2022, a note to a shareholder that was originally due on January 20, 2022 with a principal amount of approximately $8,000 ($10,000 Canadian Funds) was reissued in the principal amount of approximately $10,000 ($12,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 20, 2022 in the approximate amount of $2,000 ($2,000 Canadian Funds).  Repayment of the note is due no later than January 20, 2024.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><br/></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"/> <p style="margin: 0px; text-align: justify; font-size: 10pt">On January 31, 2022, a note to a shareholder that was originally due on January 31, 2022 with a principal amount of approximately $53,000 ($70,000 Canadian Funds) was reissued in the principal amount of approximately $66,000 ($84,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 31, 2022 in the approximate amount of $11,000 ($14,000 Canadian Funds).  Repayment of the note is due no later than January 31, 2024.</p> 2022-01-20 10000 2024-01-20 2022-01-31 66000 2024-01-31 EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

U(:, M7G"3E&.F'H2*<6 M?V"RKQ'3DQ)WE728W^+I7<=3%$;!51;IINJ06P>H)3X@%H0,4I!V?CUI_6>M M,$ANXTB(U(U=K:BL(W H!V+Q$H1$V(X?"2>Z0RA+Y&XH\'UH"9G \J/Y Y-& M@R\RO# $J&Z3;0!Y%>RK:)K1S_"XHWY[^-Y*R -V3)Y;KK+H(VK+S-\1Z^^BS:#N6F&IH_):TQ_ 0\D MT%##W+;E=M\-Z*D7PW#K08:[L>N>:IV7P$6\7GW=P&7+QQF>-USDX$<+ZPF+CMASCHWOLG_P)0 M2P,$% @ 3')"5(Y]T?/X!0 5!( !D !X;"]W;W)K&ULK5A=;]LV%'W7K[CPO"$!5%N2/]-\ (Z38"W6)$B\#<.P!UJB M(Z(2J9)4'?_[75*R+%NVMS9]22B9//?<M6.OL M?;>KPIBF1'5$1CG^LA R)1HOY4M799*2R"Y*DV[@><-N2AAO75W8>X_RZD+D M.F&9H2N;JFB5A>MOS6^L83>XFUN=&]NLC("WVF^O?L4>)5MT*)6$JY M8H*#I(O+UL1_?]TW\^V$/QA=JMH83"9S(3Z;BP_197K7$+(KH@>:*?Q/)76N8S M,'BA2)3]"\MB;@\GA[G2(BT7(X.4\>(_>2UUJ"T8>P<6!.6"P/(N EF6-T23 MJPLIEB#-;$0S YNJ78WD&#>F/&N)OS);G^;S&YOX''R-/L+9D^3^^?) M=/;AX?[YHJL1W\SJAB76=8$5', Z@T^"ZUC!+8]HM+V^B[PJM5R?8L7N]0LC0AFD;P2*1>P4P2KH@M#@5_3^9*2[SZYTB< M?A6G;^/T?XBHQ['N'V:W,(!??AH'OG\.AZ%A%E.8BC0C? 59+L,8BS4"HA35 MREE(D8+>S+!XHW.%-28EY1JF,:,+N'VE86[V"3PL%BRD$D[,S, [G]X^V)%_ M?@J$1\XS#275N(^[,VP&*I=FKJ(4N- 4AJ<=V%9[$GTE/*2J3G--PC'-!=<7 M'.X8QYF,)$T.=QL.F)T3,]P?DH4D258.*0)$]2PA%9QA3,1WL(])HAE_ ?J* M+4U1=;XA%>72_&*6^=FNQ#4QGX'TGP M/#669F25FIM,V2A<@,&5J!SA\#'G%'J>9=GKP(Q150 MTT'V"V\ WO3=$]DA69)U9:>(Y1B%@D$94*)LHDMA]M5]IZ]<0D@J\$&>7* MR7 #,:6$7-D*5]BGD:\U$?!AIS2"F1+*,*V097AW3I)"9+2UW1^.W:$WLI73 M[HWZ;C#:\=&U@B)U FI#WBRN4;)F*EI2,%[G*"SN81JY,*=$;EGI>S]OW'-M MNC'!O8T/,U0?ZR B!@;[X(NA;GO$1\)SW-40%#8&AM&F*"MO'SA,,-4$_,%: M.<'+S=_( 8M#6_-QLV(DLUW+&G6V00I124U$DHHIX')^TSSPZFA).(81'>Y3Q2IS:EK"^-S8CIX$; M,ZP7Q$GRJ&PVZZR:^%F2JYHC=K.9EFS,V^-\N2L5[L MW:\-?[XWO<;.)LNNGL_$3%;:)_$^C<'[AN#7 ^2\#CBG? M8+FK/;1MJ,.:.DU-2U"G!-U6-?#?LDD:,$=E[7VCK+WA#Y8U."SK\+ME#?;* M^J;>TX Y*FO0=P??(FMPYO9_K*R'.@4^7-RS[Y6UW@.J!^39FV3=A3G4U)UF M4U_WN,%;6OHNZ* $';ZAGQ\SJ)%OPZ M0DY[-!B;/O[F-EX]EL_6)MX<.\8V MSU1.X?*VLT;E4F,2131KGE\-'45M33LU\'FU6VG/4$N>OWBU$CJ\/0?\4TN+5E"P* M^:@]^QB-;:X=F)2>5BCVL-H/W.%HZ-@C:Z_G^KU@YYQ^_#"Y?;XK2TUMV@%6 MBD NLJJHA)$Y2U!TJCK[7D2[M3=]?&-ZL=\S\"7.5%KQTE_=K3Z93(HO!9OI MQ?<6Y(I5KB"A"USJ=4:#%LCB&T9QH45FOQO,A=8BM<.8$BP1,P%_7PCTL;PP M :H/25?_ E!+ P04 " !,&=4 % #4"@ &0 'AL+W=ON8S9TT.1 ME^ZPDWE?[?=Z+LFX4"XV%9H739.3H( M>U-[=&!JG^N2IY9<713*/HXY-ZO#SJ"SWKC6R\S+1N_HH%)+GK&_K:867[V- ME5077#IM2K*\..R,!OOC79$/ G]J7KFM-4DDST!1#GG'BQH/!S MS\>8M3C7T_-'YY,))3#N#+@W[P\$+]G8VT>\$>SO/V#LS)EWI/"=5 MIG1>>E4N]3QG&CG'WM&)=DEN7&V9_A[-G;?@T#\ON-W=N-T-;G?_GZ2_:%RZ M>-]5*N'##MK4L;WGSM'EUK:<1KKT!IELLD?3VB89^H5&2\N,/O:D2UIE.LF^TZY: MN902MAYC!&(>78JVK55.E<4 LOY1E/D!DN62"<,(6/K=?C_\12Y3")7,8MMR M"/;=!T>)*0H, /12 *J:A@O?82ETRE;%08'1.=,E=(I M*1\ZYK%D6"6/:I+2PIB"G:>G0^Y "*6 MH&!]"W,7?AZ54-"4D>P/]GRVCFMAF->V[+!@.TEG*V-A-#!NKK4W^K@,*T3!"O= MZSE(YB"=<;HI[E:> "E0.9A-5.6E\15ER%9(C[&B BL1[J\[4#S03K@C5F[C M69/VFW6^'FFZR98ND[Q.&;@1,91*XRG7A?;@B#?[T2BF*7+#ID#4TK8*7;&5 M[:9OUE:VBP6R2-C1.)9 YKIL\IZRT\NR 2.9<-$Q7 \N#>%AM1JNF5F',Q$ M)S\(G;8UCB8(SZJ4)?@F]5*ZJA5[.HI.8]H;]#_1[6Q$IR>C+F WKX=P#4/O M4VE6;S+,S$#@)[)$9S&-8/,8O LE]5:K'-5^%1X+4J#:\>OH(T*=D#BC5^=2 ML29FE;^.SF.Z9C0Q!M(#7>BYE=A:FDKZC$49E62]+=N70,Z/#=>W:A='O\?/ M'M(?XZ_1IYAFC^BV0%3A4,NI,(>.5;/$%'F: W.#&R8$AF2PQ+9&H5SH\FM. MW]"5NJ,Q8@N,".3=CP8Q?4TP%&&N4(1Q;(-: GQ"V);E<31$ A,(2OA=&7P; M/K0BTEV*4ELO >U>)QQ'.ULZ@D>1K^<4Z[!T3PZ-KN; M)]NH>:D\B3?OO<\*?8L,Y;R :C]^M]=I!M/ZPYLJO%N0-;R"PA(C"1D0 9PO M#/JE_1 'FX?LT;]02P,$% @ 3')"5&R"Y?;O @ '@8 !D !X;"]W M;W)K&ULK55+<]HP$+[W5^RXG9XRV!CR: K,\&K+ M <(4VAXZ/0A[;6LB2ZXD0_+ONY(-H3,-IQX2Z['?MP_M?@P.2C^: M'"4RFD M&0:%M=5]&)JDP)*9CJI0TDVF=,DL;74>FDHC2SVH%&$<13=AR;@,1@-_MM:C M@:JMX!+7&DQ=EDP_3U"HPS#H!L>#KSPOK#L(1X.*Y;A!^ZU::]J%)Y:4ER@- M5Q(T9L-@W+V?])V]-_C.\6#.UN RV2GUZ#:+=!A$+B 4F%C'P.BSQRD*X8@H MC-\M9W!RZ8#GZR/[)Y\[Y;)C!J=*_."I+8;!70 I9JP6]JLZ?,$VGVO'ERAA M_'\X-+;7<0!);:PJ6S!%4'+9?-E36X&:NI M:7Y=\-H_>>U[K_W_5>6+=&Y0[TW%$AP&-(D&]1Z#T>IA.W]S"^_?WL7=[D>X MZ!*V!5+J9<7D,W #4EEJ-JVI+((.Y%Z)/:;4BK;P54H5-D8%VR,\2G40F.8( M*@/'0 J14A%!:; %28-%26C!+<]9,WLYR8.Q=/OBEHS])P-.;Z&RC">H30IC=< ,G4$[[K1513Y/PH5DN,+6KT$0DUM[XI -64OV']U4'@VLR7JW"N3H3")N1G?T^E)_,;- MS+^8-\JY9#JG\H+ C*!1Y_8Z -VH4;.QJO(*L%.6],0O"Q)PU,Z [C-%]6XW MSL'I)V'T!U!+ P04 " !,I!51G&4?0ZK(14P6+FYW9F M,=.-*Z7"G0';5)4PQQ66NIT'DZ"?>)!YX7@B7,QJD>,>W>_USM H'%A26:&R M4BLPF,V#Y>3M:LKQ/N /B:T]>P>NY*#U$P_NTGD0L2 L,7',(.CO*ZZQ+)F( M9'PY<09#2@:>O_?LM[YVJN4@+*YU^:=,73$/;@)(,1--Z1YT^P%/]5PS7Z)+ MZW^A[6+C.("DL4Y7)S IJ*3J_L7SR8C2)DXH79>\,?96$WJWO M'F>AHP0<%B8GLE5'%K] ]BM\TLH5%K8JQ?1[?$C"!G5QKVX57R3<8#*&J\D( MXBB>7."[&JJ]\GQ7+_!MOS32'>&OY<$Z0QOB[PNP.J 9W!O!G4&%\!Z=.XZ@+32= M*2MS1<'"@H"JB]>9IUQI85(>;*2A Z2-'0%9IFR&QA!D>CV*HH@?L(4@)HY- M=$4B@#9M\D3[V!4@%*!UDDX/83(A#7P598,<_&-' 4[#>X.Y-D?8R5(H1R#6 M?]!&%/U44Q,OZ2("4==:*D>-P;'P09^'W6>93-#8OHRUKFJACN/SXDFFBT&7*R%;Q^E3:< 8R8A+] MU-/UEC7..I+-<<)U2TD=;PR/WU+2*B6:,OQ#!GIC?^$FE++7U)BM\+WMS$ZV M72K(2::A.M@4D5+CD+SCN0,"/C.0TDMO*37&I$O%,DB/0^\M<5+K-SZ!)16E M7T-RC/CML!UD3C_^KY,9GO6Y"DWNN[DEWD:YKN4-L\.%L>SZY+?P[K;Y)$PN MJ:X2,X)&XS?7 9BN@W<#IVO?-0_:40_VKP5=>F@X@+YGFBH]#3C!<(TN_@50 M2P,$% @ 3')"5&U(F=7W @ _@< !D !X;"]W;W)K&ULM95M;],P$,??]U.A:;4R#+O5(@PB:*#L&!;B3.^RJV;"">CDJUPCO:\/-4T"EM*Q@N4ABL)&I?CX"A^ M/1TX>V_PC>/:;/7!1;)0ZL(-WF?C('*"4&!J'8'1YPJ/40@'(AF7#3-HMW2. MV_T-_<3'3K$LF,%C);[SS.;C8!A ADM6"7NFUN^PB6??\5(EC&]A7=LFAP&D ME;&J:)Q)0<%E_67731ZV'(;1(PY)XY!XW?5&7N5;9MEDI-4:M+,FFNOX4+TW MB>/2%65N-:UR\K.3^?ET/OMR/OOT%6;?J)V/0DM8MQBF#6):(Y)'$(?P44F; M&YC)#+.[_B'):34E&TW39"?P+:8]Z,==2*(DWL'KMS'V/:__6(S5PN!EA=+" M[(I: S^.%L9J.A$_=^ '+7[@\8.GI' WXM/GKS,XA.?/ADDAI/C$)%U@':DL@E7 P.1,8ZY$AAILSBRLF0&E^8I+)L0-9!6"N@^A MTV9S I6:RY273 K5$6)4DM@9:G5-:>3CP38&W:C*((7>W'D.\=,LHPS"2>5 MS,Q+OY]&;DR%68=+$H'P!]2&1MCD(6RWL\YYF@-Q1$6GRV,W8=WGEZ(R9&M1 MH['TQZ>:U IHX0TH7?:T!N16X*V9.XEC:X'9?7@#$MV4V!M[#"^%-SX1$L% M@G"^$O+WC0>][6HVQ_QIU=Q _J*:^_TFOE?_M)P'!PUV./B_Y>S-X M<\[N"NO\84$[]PNZV7K0>^@2";?NY +URK\\!E*GJ+Z>V]GV<3NJ[_1;\_IE M_,@T)_F]$"C=@:TOE042S-P&[1/ M_N074$L#!!0 ( $QR0E3BNZ H@4 &$- 9 >&PO=V]R:W-H965T MG0FEWTB[-L1"N:TK4M+,PMA">'NVRYTJ+(@M"A>H-^_W37B&D;EV>AW=W]O+< M5%Y)C7<67%44PFZN4)GU16O0VKZXE\O<\XO>Y7DIECA#_UC>67KJ-2B9+% [ M:3187%RTQH,W5V=\/ASX2^+:[:R!+9D;\YD?IME%J\^$4&'J&4'0WPHGJ!0# M$8TO-6:K4\N#RW M9@V63Q,:+X*I09K(2C.=C&\?8#R9?'R\?9C>OH>[ MCW].)]/K&1S=&253B:Y]WO.DCZ5Z:8U]%;&'+V#_#A^,]KF#:YUA]ER^1SP; MLL,MV:OA0ZF7L#43_A[/G;>4 M+/\<4'#<*#@."HY?4'"/*]05PCVF9JDEY^$^-_X42+(# @\Y)A-3E$)O*&&4 MHOI(CI)/*3AL* 'XG-_4^4:" MPW;RW6DHT886H%,$,U=R*9B( ZFCZ!9LU*:B\&@I5[>*:$,[$:NPM#+%#ARW M02AE4N&W^/\Y!-X$:8M?*FDQVV60'�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end XML 37 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 38 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 66 206 1 false 13 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://regenerex.avantafile.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://regenerex.avantafile.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://regenerex.avantafile.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://regenerex.avantafile.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS Sheet http://regenerex.avantafile.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DIFICIT Sheet http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit STATEMENTS OF STOCKHOLDERS' DIFICIT Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://regenerex.avantafile.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS Sheet http://regenerex.avantafile.com/role/BasisOfPresentationOfInterimFinancialStatements BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://regenerex.avantafile.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://regenerex.avantafile.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://regenerex.avantafile.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY Sheet http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualProperty INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://regenerex.avantafile.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? DEFICIT Sheet http://regenerex.avantafile.com/role/StockholdersDeficit STOCKHOLDERS??? DEFICIT Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://regenerex.avantafile.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://regenerex.avantafile.com/role/NatureOfOperations 17 false false R18.htm 00000018 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://regenerex.avantafile.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://regenerex.avantafile.com/role/GoingConcern 18 false false R19.htm 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://regenerex.avantafile.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://regenerex.avantafile.com/role/RelatedPartyTransactions 20 false false R21.htm 00000021 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative) Sheet http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative) Details http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualProperty 21 false false R22.htm 00000022 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://regenerex.avantafile.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://regenerex.avantafile.com/role/StockholdersDeficit 22 false false R23.htm 00000023 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://regenerex.avantafile.com/role/SubsequentEvents 23 false false All Reports Book All Reports ixform10q.htm exhibit31-1.htm exhibit31-2.htm exhibit32-1.htm exhibit32-2.htm rep1357878-20211231.xsd rep1357878-20211231_cal.xml rep1357878-20211231_def.xml rep1357878-20211231_lab.xml rep1357878-20211231_pre.xml regenerexlogo.gif http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 41 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ixform10q.htm": { "axisCustom": 0, "axisStandard": 3, "contextCount": 66, "dts": { "calculationLink": { "local": [ "rep1357878-20211231_cal.xml" ] }, "definitionLink": { "local": [ "rep1357878-20211231_def.xml" ] }, "inline": { "local": [ "ixform10q.htm" ] }, "labelLink": { "local": [ "rep1357878-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rep1357878-20211231_pre.xml" ] }, "schema": { "local": [ "rep1357878-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 191, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 26, "http://regenerex.avantafile.com/20211231": 3, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 34 }, "keyCustom": 3, "keyStandard": 203, "memberCustom": 9, "memberStandard": 4, "nsprefix": "rep1357878", "nsuri": "http://regenerex.avantafile.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://regenerex.avantafile.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://regenerex.avantafile.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://regenerex.avantafile.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY", "role": "http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualProperty", "shortName": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://regenerex.avantafile.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 DEFICIT", "role": "http://regenerex.avantafile.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUBSEQUENT EVENTS", "role": "http://regenerex.avantafile.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "role": "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - GOING CONCERN (Details Narrative)", "role": "http://regenerex.avantafile.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-10-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - BALANCE SHEETS", "role": "http://regenerex.avantafile.com/role/BalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-11-012021-11-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)", "role": "http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative", "shortName": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-11-012021-11-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "role": "http://regenerex.avantafile.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2022-01-012022-01-20_custom_PromissoryNote1Member", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2022-01-012022-01-20_custom_PromissoryNote1Member", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2020-10-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS", "role": "http://regenerex.avantafile.com/role/StatementsOfOperations", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2020-10-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - STATEMENTS OF CASH FLOWS", "role": "http://regenerex.avantafile.com/role/StatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - STATEMENTS OF STOCKHOLDERS' DIFICIT", "role": "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit", "shortName": "STATEMENTS OF STOCKHOLDERS' DIFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "role": "http://regenerex.avantafile.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS", "role": "http://regenerex.avantafile.com/role/BasisOfPresentationOfInterimFinancialStatements", "shortName": "BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "role": "http://regenerex.avantafile.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ixform10q.htm", "contextRef": "From2021-04-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 13, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r256", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://regenerex.avantafile.com/role/Cover" ], "xbrltype": "booleanItemType" }, "rep1357878_AccruedInterestConvertedIntoNotePayableToShareholder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest converted into note payable to shareholder" } } }, "localname": "AccruedInterestConvertedIntoNotePayableToShareholder", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rep1357878_April15Note2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April 15 Note 2021 [Member]" } } }, "localname": "April15Note2021Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_CommonStockIssuedForPurchaseOfIntellectualProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for purchase of intellectual property" } } }, "localname": "CommonStockIssuedForPurchaseOfIntellectualProperty", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "sharesItemType" }, "rep1357878_December9Note2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 9 Note 2021 [Member]" } } }, "localname": "December9Note2021Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_NotePayableToShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable To Shareholder [Member]" } } }, "localname": "NotePayableToShareholderMember", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_October11Note2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 11 Note 2021 [Member]" } } }, "localname": "October11Note2021Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_October21Note2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 21 Note 2021 [Member]" } } }, "localname": "October21Note2021Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_October25Note2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 25 Note 2021 [Member]" } } }, "localname": "October25Note2021Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_PromissoryNote1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note 1 [Member]" } } }, "localname": "PromissoryNote1Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_PromissoryNote2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note 2 [Member]" } } }, "localname": "PromissoryNote2Member", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_PurchaseIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Intellectual Property [Member]" } } }, "localname": "PurchaseIntellectualPropertyMember", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rep1357878_StockIssuedDuringPeriodPurchaseOfIntellectualProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockIssuedDuringPeriodPurchaseOfIntellectualProperty", "verboseLabel": "Common stock issued for purchase of intellectual property" } } }, "localname": "StockIssuedDuringPeriodPurchaseOfIntellectualProperty", "nsuri": "http://regenerex.avantafile.com/20211231", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "sharesItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingCurrentAndNoncurrent": { "auth_ref": [ "r228", "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to vendors that bear interest at either a stated or an imputed rate.", "label": "Accrued Interest" } } }, "localname": "AccountsPayableInterestBearingCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Other accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r167", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r63", "r64", "r65", "r164", "r165", "r166", "r177" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash flows used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r50", "r105", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.", "label": "Asset Acquisition, Contingent Consideration, Liability" } } }, "localname": "AssetAcquisitionContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability [Abstract]" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r59", "r84", "r87", "r93", "r100", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r173", "r175", "r180", "r205", "r207", "r224", "r233" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r31", "r59", "r100", "r114", "r115", "r116", "r118", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r173", "r175", "r180", "r205", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.", "label": "Business Combination, Contingent Consideration Arrangements, Description" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualPropertyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r62", "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BasisOfPresentationOfInterimFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r19", "r52" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets", "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r46", "r185" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Decrease in cash and equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash Investing and Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r110", "r111", "r112", "r113", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r63", "r64", "r177" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r41", "r59", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r180" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r10", "r11", "r58", "r61", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r195", "r225", "r226", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r127", "r144", "r145", "r193", "r195", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26", "r128" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r28", "r130" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.", "label": "Debt Instrument, Issuance Date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r27", "r130", "r179" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, End" } } }, "localname": "DebtInstrumentMaturityDateRangeEnd1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date Range, Start" } } }, "localname": "DebtInstrumentMaturityDateRangeStart1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29", "r58", "r61", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r195" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative", "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r50", "r109" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r20", "r60", "r117", "r119", "r120", "r124", "r125", "r126", "r200" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related party advances", "verboseLabel": "Related Party Advances" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets", "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r185" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Foreign currency adjustments" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r63", "r64", "r65", "r67", "r72", "r74", "r78", "r101", "r160", "r161", "r164", "r165", "r166", "r168", "r169", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r239", "r240", "r241", "r265" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated Amortization, Website" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r106", "r211" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Website, net of accumulated amortization of $21,974 and $19,645, respectively" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r181", "r182", "r183", "r184" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign currency gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r40", "r59", "r84", "r86", "r89", "r92", "r94", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r180" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Loss" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Basic and Diluted Loss per Common Share" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r47", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r49" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r49" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "verboseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/IntangibleAssetsAndIntellectualProperty" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r37", "r83", "r192", "r194", "r230" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r59", "r88", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r174", "r175", "r176", "r180", "r205", "r206" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r59", "r100", "r180", "r207", "r227", "r236" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r59", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r174", "r175", "r176", "r180", "r205", "r206", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r48", "r51" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r32", "r33", "r36", "r39", "r51", "r59", "r66", "r68", "r69", "r70", "r71", "r73", "r74", "r75", "r84", "r86", "r89", "r92", "r94", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r178", "r180", "r229", "r238" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows", "http://regenerex.avantafile.com/role/StatementsOfOperations", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Total Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r11", "r226", "r234" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable to shareholder, net of current portion", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets", "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable to shareholder" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r84", "r86", "r89", "r92", "r94" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r44" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedLabel": "Website" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r7", "r102", "r103" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r45" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable to shareholder" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r45" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "verboseLabel": "Related party advances" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the preproduction design and development costs it incurs related to long-term supply arrangements, including whether such costs are capitalized or expensed as incurred. The entity also may disclose the aggregate amount of (1) assets recognized for agreements that contractually reimburse the entity for its pre-production design and development costs (2) assets recognized for molds, dies and other tools that the entity owns and (3) assets recognized for molds, dies and other tools that the entity does not own.", "label": "Website" } } }, "localname": "PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r163", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r163", "r199", "r202", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r197", "r198", "r200", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r161", "r167", "r207", "r235", "r242", "r243" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r63", "r64", "r65", "r67", "r72", "r74", "r101", "r164", "r165", "r166", "r168", "r169", "r177", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r38", "r59", "r81", "r82", "r85", "r90", "r91", "r95", "r96", "r97", "r100", "r114", "r115", "r116", "r119", "r120", "r121", "r122", "r123", "r125", "r126", "r180", "r231" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://regenerex.avantafile.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Share-based Payment Arrangement, Noncash Expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfCashFlows", "http://regenerex.avantafile.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r30", "r34", "r35", "r36", "r63", "r64", "r65", "r67", "r72", "r74", "r78", "r101", "r160", "r161", "r164", "r165", "r166", "r168", "r169", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r239", "r240", "r241", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r63", "r64", "r65", "r78", "r210" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/NatureOfOperationsDetailsNarrative", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r59", "r99", "r100", "r180", "r207" ], "calculation": { "http://regenerex.avantafile.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total Stockholders\u2019 Deficit", "negatedLabel": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at December 31, 2021", "periodStartLabel": "Balance at September 30, 2021" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/BalanceSheets", "http://regenerex.avantafile.com/role/GoingConcernDetailsNarrative", "http://regenerex.avantafile.com/role/StatementsOfStockholdersDificit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r57", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Common Shares Outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://regenerex.avantafile.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105117-122735" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r245": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r246": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r247": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r248": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r249": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r251": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r252": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r253": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r254": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r255": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r256": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r257": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r258": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r259": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r261": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r262": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r263": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r264": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" } }, "version": "2.1" } ZIP 42 0001472375-22-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001472375-22-000012-xbrl.zip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